Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Humanin
Beginner tier: 1 mg, EOD · preclinical extrapolation
Also known as: HN, MT-RNR2, HNG (S14G-Humanin analog)
Circulating levels drop measurably with every decade of life. Humanin is a 24-amino acid peptide encoded directly in mitochondrial DNA, first isolated from surviving neurons in an Alzheimer's patient's brain back in 2001. No human clinical trial has been completed, and the cancer safety question remains open; two preclinical studies show the same anti-apoptotic mechanism that protects neurons also shields tumor cells. Longevity-focused biohackers pair it with MOTS-c in mitochondrial stacks, though dosing protocols are entirely extrapolated from rodent data and community self-experimentation.
What Is Humanin?
Circulating humanin levels decline with age across every population studied so far. That single observation launched two decades of research into whether replacing this 24-amino acid mitochondrial-derived peptide (MDP) could slow aspects of aging.
Nishimoto and colleagues first isolated humanin in 2001 from the occipital lobe of an Alzheimer's disease patient (CAS 330936-69-1; also known as HN, MT-RNR2-derived peptide). The peptide sits within the 16S ribosomal RNA gene of mitochondrial DNA, making it one of several bioactive molecules encoded outside the nuclear genome. MOTS-c belongs to the same family.
The mechanism is multi-pronged. Humanin directly binds the pro-apoptotic protein BAX, blocking it from puncturing the mitochondrial outer membrane. It activates JAK/STAT3 signaling through a trimeric receptor complex (CNTFR, WSX-1, gp130). It also binds IGFBP-3, preventing IGF-1-independent apoptosis. The result across cell and animal models is broad cytoprotection; neurons, cardiac cells, retinal tissue, and pancreatic beta cells all benefit.
A 2020 study in Aging [1] tracked HNG-treated mice and found better cognitive performance, improved metabolic markers, and reduced inflammatory signaling compared to controls. Insulin sensitivity improvements appeared consistently across rodent studies.
The catch is real. Zero completed human clinical trials exist. All published dosing data comes from intraperitoneal injection of HNG (the S14G analog, roughly 1,000x more potent than native humanin) in mice and rats. Rat PK data from Chin and colleagues [2] showed humanin undetectable in brain tissue after systemic injection. Two preclinical studies document humanin actively promoting tumor progression in triple-negative breast cancer (Scientific Reports 2020) and glioblastoma invasion (Cell Death and Disease 2024).
How Humanin Works
Humanin operates through three distinct signaling axes, each converging on a single outcome: cell survival.
On the extracellular side, humanin binds a trimeric receptor complex composed of CNTFR, WSX-1, and gp130. This triggers JAK/STAT3 signaling, which upregulates anti-apoptotic gene expression. Humanin also engages formyl peptide receptors FPRL1 and FPRL2, activating ERK 1/2 phosphorylation. That pathway links to both neuroprotection and inflammation modulation.
Inside the cell, the picture gets more specific. Humanin directly binds BAX, a pro-apoptotic BCL-2 family protein. By sequestering BAX, it prevents translocation to the mitochondrial outer membrane. No pore formation means no cytochrome c release, which shuts down the caspase cascade before it starts. Humanin also binds tBID, blocking the BAX/BID oligomerization that amplifies membrane permeabilization (Morris et al.)[3].
The third axis involves IGFBP-3. Humanin binds IGFBP-3 and prevents it from triggering its IGF-1-independent cell death program. Interestingly, this same binding accelerates humanin's plasma clearance; analogs like HNGF6A that skip IGFBP-3 binding circulate longer in rodent models.
At the mitochondrial level, humanin localizes to lysosomal membranes and activates chaperone-mediated autophagy. It also triggers the PI3K/AKT pathway, promoting mitochondrial biogenesis and improving respiratory chain efficiency.
The double-edged nature of all this is worth sitting with. Every pathway that protects a healthy neuron from apoptosis can just as easily protect a tumor cell.
Humanin Benefits
- Humanin benefits center on cytoprotection, metabolic support, and mitochondrial defense across preclinical models.
- Protects neurons from amyloid-beta toxicity through direct BAX inhibition and STAT3 activation, confirmed across multiple in vitro and rodent studies (Biology 2023 review covering 20+ years of published data)[4].
- Improves insulin sensitivity and fasting glucose in mouse models; Yen et al. [1] tracked HNG-treated mice showing metabolic marker improvements alongside reduced inflammatory signaling over a multi-week protocol.
- Reduces oxidative stress and preserves mitochondrial membrane integrity across neural, cardiac, and retinal tissue models, making it one of the broadest cytoprotective peptides studied preclinically.
- Circulating levels decline with age across measured human populations, suggesting exogenous replacement may counteract age-related loss of endogenous mitochondrial-derived peptide signaling.
- The HNG analog (S14G substitution) offers roughly 1,000-fold greater potency than native humanin, which is why almost all published animal efficacy data uses HNG rather than the wild-type peptide.
- Users in the longevity community report subjective cognitive clarity and energy when stacking with MOTS-c, though the community evidence base is small (roughly 20 to 40 Reddit threads across r/nootropics, r/longevity, and r/Biohackers).
Humanin: Science vs Community Consensus
Neuroprotective and anti-apoptotic in vitro and animal models; improves insulin sensitivity and metabolic markers in rodents; lifespan extension in C. elegans and mouse models.
Read the evidence (key study, limitations)
No completed human clinical trials as of October 2026. CNS penetration via systemic injection undetectable in rat PK data (PMC3776863), undermining neuroprotection claims for SC dosing. Two published studies document humanin as a pro-tumoral factor: TNBC tumor progression (Sci Reports 2020) and GBM invasion via integrin αV–TGFβ axis (Cell Death & Disease 2024). Virtually all mechanistic and efficacy data uses HNG (1,000x more potent analog), not native humanin.
Chin et al. 2013 (PMC3776863): PK and tissue distribution in rodents; Yen et al. 2020 (PMID 32575074): humanin as healthspan regulator in mice; Nishimoto et al. 2000 (original discovery from AD brain)
No human interventional trials completed. All dosing extrapolated from animal IP injection studies. Human PK (half-life, bioavailability, CNS penetration) entirely unknown. Most published research uses HNG, not native humanin: results cannot be directly translated. Cancer promotion documented in two distinct preclinical models. IGFBP-3 binding dynamics differ between species, making PK extrapolation unreliable.
Intellectually compelling longevity and neuroprotection peptide with very limited self-report data.
Read the reports (what users report 3, common issues 4)
Most users combine with MOTS-c in a "mitochondrial MDP" stack. High cost and half-life logistics limit adoption. No community consensus on effective dose or measurable cycle outcome.
- Subjective cognitive clarity and calm reported in limited anecdotal accounts
- Perceived energy and mitochondrial support when stacked with MOTS-c
- No major adverse events at community doses reported publicly
- ~30-min half-life in mice creates uncertainty about dosing frequency adequacy for sustained tissue exposure
- Native vs. HNG form not reliably labeled on products: major source of confusion and potential dosing error
- Very high cost (~$15–20/mg native humanin) limits sustained protocol adherence
- No subjective biomarker tracking to confirm efficacy
Community interest mirrors scientific targets (neuroprotection, mitochondrial support, anti-aging) but the community largely lacks awareness of: (1) the 2024 Cell Death & Disease GBM invasion data (integrin αV–TGFβ axis: a new cancer mechanism distinct from anti-apoptosis), (2) rat PK data showing humanin undetectable in brain tissue after systemic injection, and (3) the native vs. HNG potency gap creating ~1,000x dosing ambiguity at the labeling level.
Humanin Dosage Guide
Confirm which form you have before doing anything else. Most research-grade humanin is HNG (S14G-Humanin), which is roughly 1,000x more potent than native humanin. Using HNG at milligram doses would be a massive overdose. Check the label and CoA for native humanin or HNG before opening the vial.
For a 5 mg native humanin vial reconstituted with 2 mL bacteriostatic water, concentration is 2.5 mg/mL. On a U100 insulin syringe, 1 mg equals 0.4 mL, which is 40 units. A 3 mg dose comes to 1.2 mL (120 units); that's a large SC volume, so consider reconstituting 5 mg in 1 mL BAC water instead (5 mg/mL, making 3 mg equal to 60 units).
Each 5 mg vial provides five doses at 1 mg or roughly 1.7 doses at 3 mg. A 10-week moderate cycle (3 mg three times weekly, 90 mg total) requires about 18 vials. At $75.99 per vial, that's around $1,368 before shipping. Plan your reconstitution timing carefully; reconstituted vials only last 21 to 30 days refrigerated.
Cycling Protocol
No established cycling protocol exists for humanin in humans. These ranges are extrapolated from general peptide cycling practices and community reports. Periodic breaks are recommended given the absence of long-term safety data. Monitor for any unusual symptoms throughout use.
No receptor desensitization or antibody formation data exists for humanin. Cycling is based on the precautionary principle given: (1) absent long-term human safety data, (2) documented pro-tumoral activity in two preclinical cancer models (TNBC and GBM), and (3) the anti-apoptotic mechanism that theoretically could protect occult tumor cells with sustained use. The 10-week on / 5-week off schedule is community-extrapolated, not evidence-based.
- Any new or unexplained mass, tissue growth, or tumor symptoms: discontinue immediately and consult a physician
- Unexplained hypoglycemia or blood sugar drops below normal fasting range
- Persistent injection site reactions beyond 48 h suggesting immune sensitization
- Any new or worsening neurological symptoms given unknown CNS pharmacology
Or use the universal Peptide Calculator for any peptide.
Humanin Protocols by Goal
Expected: No validated human outcome data. Animal models suggest potential insulin sensitivity and inflammatory marker improvements over 4–12 weeks of consistent dosing. Cognitive or neuroprotective effects from peripheral SC dosing have no established CNS mechanism.
Monitor: Fasting glucose at baseline and week 6. Cancer screening before starting: anti-apoptotic mechanism is a hard contraindication with any cancer history.
How to Use Humanin
- 1Step 1
Reconstitute the 5 mg vial by adding 2 mL bacteriostatic water slowly along the glass wall. Don't spray directly onto the powder. Swirl gently until fully dissolved. Never shake.
- 2Calculate your dose
At 2 mL BAC water per 5 mg vial, concentration is 2.5 mg/mL. For a 1 mg dose, draw 40 units on a U100 insulin syringe (0.4 mL). For a 3 mg dose, draw 120 units (1.2 mL), or reconstitute with 1 mL BAC water for a 5 mg/mL concentration and draw 60 units instead.
- 3Clean the injection site with an alcohol swab
Preferred areas: lower abdomen (avoiding a 2-inch radius around the navel) or upper outer thigh. Rotate sites each injection.
- 4Step 4
Pinch the skin and insert a 29 to 31 gauge insulin syringe at a 45-degree angle. Inject slowly. Hold for 5 seconds before withdrawing.
- 5Step 5
Administer in the morning or early afternoon on an empty stomach. The beginner protocol is 1 mg every other day; the moderate protocol calls for 3 mg three times per week (Mon/Wed/Fri).
- 6Store the reconstituted vial at 2 to 8 degrees Celsius
Use within 21 to 30 days. Never freeze reconstituted solution. Lyophilized vials store at minus 20 degrees Celsius or colder for 12 to 24 months.
Alternative Routes
No human intranasal dose established. Mouse studies used intranasal HNG over 3 months. No human dose equivalent derived.
Intranasal delivery may achieve CNS penetration that systemic injection cannot: rat PK data (PMC3776863) shows humanin undetectable in brain tissue after IP injection. Not commercially available as intranasal formulation. Some researchers have explored DIY nasal spray reconstitution, but this is non-standard and raises sterility concerns. Mechanistically superior to SC for CNS targets based on mouse data.
All animal efficacy data (2.5–4 mg/kg HNG, IP) used IP route. SC bioavailability relative to IP is unknown in humans.
IP injection is not a human self-administration route. Noted only to contextualize why all published animal dosing data is difficult to directly translate into human SC protocols.
Humanin Stacking Protocols
Works With
Most frequently cited MDP combination in longevity community. MOTS-c acts primarily via AMPK on nuclear gene expression and metabolic regulation; humanin acts on apoptotic signaling (BAX inhibition, JAK/STAT3). Complementary targets within the mitochondrial-derived peptide family.
Humanin Mon/Wed/Fri SC; MOTS-c Tue/Thu SC
Additive mitochondrial membrane protection. SS-31 stabilizes cardiolipin on the inner mitochondrial membrane; humanin inhibits BAX-mediated outer membrane permeabilization. Complementary mechanisms. Note: SS-31 has human Phase 2 trial data; humanin has none.
Longevity protocol framing. Different mechanisms (humanin: apoptosis inhibition; Epithalon: telomerase activation/pineal regulation). Often cycled together in anti-aging stacks. Humanin carries documented cancer risk signal that Epithalon does not.
Anti-aging cytoprotective stack. GHK-Cu promotes tissue repair and antioxidant gene expression; humanin inhibits mitochondrial apoptosis. No known interaction concerns at community doses.
Avoid
Humanin's anti-apoptotic mechanism (BAX inhibition, STAT3 activation) may protect cancer cells from chemotherapy-induced programmed death. Documented in GBM (Cell Death & Disease 2024: integrin αV–TGFβ axis) and TNBC (Sci Reports 2020). Risk of blunting therapeutic efficacy of any pro-apoptotic cancer treatment.
Do not combineHumanin binds IGFBP-3 and partially antagonizes the GH/IGF-1 signaling axis. Concurrent use may blunt intended GH/IGF-1 effects. Magnitude of antagonism in humans is unknown but mechanistically documented in animal models.
Humanin improves insulin sensitivity via hypothalamic STAT3 and β-cell mechanisms in animal models. Co-administration with insulin or sulfonylureas may increase hypoglycemia risk.
Therapies relying on apoptosis induction (senolytics such as navitoclax, dasatinib; BCL-2 inhibitors) may be mechanistically antagonized by humanin's BAX-inhibiting activity. Combined use not studied; antagonism is biologically plausible.
Estimated Cost
Pricing updated 2026-04-09
Humanin Side Effects
The cancer risk is the single biggest safety flag in humanin research, and it deserves front position. A 2020 study in Nature Scientific Reports showed humanin actively promoted tumor progression in triple-negative breast cancer mouse models. A 2024 paper in Cell Death and Disease documented a second, mechanistically distinct cancer pathway: humanin facilitated glioblastoma invasion via the integrin alphaV-TGFbeta axis. These aren't theoretical concerns extrapolated from mechanism. They're published experimental results.
Humanin's core biological activity, inhibiting BAX-mediated apoptosis, is the same mechanism that would protect cancer cells from programmed death. Anyone with active cancer, a cancer history, or strong genetic predisposition (BRCA mutations, Lynch syndrome) should treat humanin as a hard contraindication. This isn't a gray area.
Beyond cancer, there are growth and reproductive concerns from animal data. Sustained humanin overexpression has impaired growth and reproductive function in animal models, likely through its antagonistic relationship with the GH/IGF-1 axis. The clinical relevance to adult human dosing is unknown, but it's reason enough to keep humanin away from anyone under 18.
Human side-effect data from actual clinical experience doesn't exist because no interventional trials have been completed. The total human evidence base for adverse effects is zero controlled participants.
In animal studies at standard research doses, humanin has been tolerated without major reported adverse events. Mild injection-site reactions (redness, swelling at the subcutaneous site) are expected with any injectable peptide and typically resolve within 24 to 48 hours.
Hypoglycemia risk increases if you're co-administering insulin or oral hypoglycemics. Humanin improves insulin sensitivity through hypothalamic STAT3 and beta-cell mechanisms in animal models. That combination benefit could push blood sugar too low.
Pregnancy and breastfeeding are contraindicated. No reproductive safety data exists in any species at relevant doses.
When to stop: any new or unexplained mass, tissue growth, or tumor symptoms. Signs of hypoglycemia. Persistent injection site reactions beyond 48 hours. Any new neurological symptoms given the completely unknown CNS pharmacology in humans. Discontinue and consult a physician.
Common Issues & Solutions
Uncertain peptide form (most critical issue): Before dosing, confirm from the label and CoA whether product is native humanin (wild-type, 24 AA) or HNG (S14G analog). HNG requires mcg-range dosing: mg-level doses of HNG would constitute a ~1,000x overdose. Many products are not clearly labeled as one or the other.
No subjective effects: With ~30-min half-life in mice and unknown human PK, EOD or 3x/week SC dosing may provide insufficient tissue exposure. Some community users switch to daily SC dosing, though this depletes expensive vials quickly (~5 doses per 5 mg vial at 1 mg each).
High cost logistics: A 10-week moderate cycle (3 mg × 3x/week = 90 mg) requires ~18 vials at 5 mg each (~$1,368 at $75.99/vial). Plan reconstitution timing carefully: reconstituted vials are only stable 21–30 days refrigerated.
Large-volume injections at higher doses: At 3 mg with standard 5 mg + 2 mL BAC water reconstitution (2.5 mg/mL), injection volume is 1.2 mL: uncomfortable for single SC injection. Alternative: reconstitute 5 mg vial in 1 mL BAC water (5 mg/mL); 3 mg = 60 units on U100 syringe, a manageable volume.
Cognitive or neuroprotective effects absent: Rat PK data (PMC3776863) shows humanin undetectable in brain tissue after systemic IP injection. SC is even less penetrant than IP. Reported cognitive effects from peripheral SC dosing lack mechanistic support: manage expectations and consider whether intranasal delivery is more appropriate if CNS effects are the target.
Ask AI about this page
Ask AI for a second opinion on Humanin dosing and side effects
Contraindications
- Active cancer or history of cancer: humanin's anti-apoptotic properties may protect tumor cells from programmed death
- Pregnancy and breastfeeding: no reproductive safety data exists
- Children under 18: humanin overexpression has been shown to impair growth in animal models
- Known hypersensitivity to humanin or any component of the formulation
- Concurrent immunosuppressive therapy: potential for unpredictable immune interactions
Drug Interactions
- Chemotherapy agents: humanin may reduce efficacy by protecting cancer cells from apoptosis
- IGF-1 / Growth Hormone therapies: humanin binds IGFBP-3 and antagonizes GH/IGF-1 signaling; concurrent use may blunt GH/IGF-1 effects
- Insulin and oral hypoglycemics: humanin improves insulin sensitivity in animal models; co-administration could increase hypoglycemia risk
- Pro-apoptotic therapies: any therapy relying on apoptosis induction may be counteracted by humanin's BAX-inhibiting activity
- Humanin's anti-apoptotic mechanism (BAX inhibition, STAT3 activation) may protect cancer cells from chemotherapy-induced programmed death. Documented in GBM (Cell Death & Disease 2024: integrin αV–TGFβ axis) and TNBC (Sci Reports 2020). Risk of blunting therapeutic efficacy of any pro-apoptotic cancer treatment.
Product Quality
Native vs. HNG mislabeling is an industry-wide issue: labels do not consistently specify which form is in the vial. HNG is ~1,000x more potent; receiving HNG labeled as native humanin while dosing at mg-level creates extreme overdose risk. No FDA oversight of research peptide isoform labeling. HPLC purity testing does not distinguish native humanin from HNG: mass spectrometry confirmation is required.
- The CoA needs to specify native humanin (wild-type, 24 AA) vs. HNG (S14G): purity % alone is insufficient for identity confirmation.
- Native humanin and the S14G/HNG analog often carry similar names; the label and CoA should state which sequence a vial contains.
- Quality benchmark: HPLC ≥98% purity AND mass spectrometry confirmation of correct molecular identity.
- Do not freeze reconstituted solution; refrigerate at 2–8°C and discard after 21–30 days.
- Store lyophilized peptide at -20°C or colder; stable 12–24 months unopened.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Fasting glucose and fasting insulin | Baseline and week 6 | Fasting glucose 70–99 mg/dL; fasting insulin <10 µIU/mL |
| Age- and risk-appropriate cancer screening | Before initiating any humanin protocol | Not listed |
| CBC (complete blood count) | Baseline | Not listed |
| Liver function panel (ALT, AST, bilirubin) | Baseline | Not listed |
Humanin improves insulin sensitivity via hypothalamic STAT3 and β-cell mechanisms in animal models. Risk of hypoglycemia increases with co-administered insulin or oral hypoglycemics.
Humanin promotes tumor progression in TNBC (Sci Reports 2020) and GBM invasion via integrin αV–TGFβ axis (Cell Death & Disease 2024). Cancer history or strong genetic predisposition (BRCA, Lynch syndrome, etc.) is a hard contraindication.
No humanin-specific hematologic signal known. Establishes baseline and identifies pre-existing conditions that may interact with anti-apoptotic activity.
No humanin-specific hepatotoxicity documented. Standard precautionary monitoring for any novel research peptide with no completed human safety trials.
Humanin Before and After
Possible improvements in subjective energy and cognitive clarity based on anecdotal reports. No clinical data supports a specific onset timeline. This is an assessment period.
Potential metabolic improvements (insulin sensitivity, inflammatory markers) based on extrapolation from animal study timelines.
Cumulative effects on cellular protection and mitochondrial function may begin to manifest. Animal studies typically show measurable outcomes by this point.
Full effects on cellular protection may require sustained administration. Most animal studies run 4-12 weeks. Reassess and decide on continuation.
What to Expect
Weeks 1 to 2 (Assessment Period): No human onset data exists for humanin at any dose or route. Rodent pharmacokinetics show peak plasma concentration at roughly 10 minutes in mice (IP) and about 4 hours in rats (IP), with brain tissue levels undetectable after systemic injection (Chin et al.)[2]. Some biohackers report mild subjective energy or cognitive clarity during the first two weeks. No objective data supports a specific onset; these effects may reflect placebo or co-administered peptides like MOTS-c or NAD+ precursors. Minor injection site redness is common and typically resolves within a day or two.
Weeks 3 to 6 (Potential Metabolic Effects Window): Animal models using HNG at 2.5 to 4 mg/kg IP showed insulin sensitivity and inflammatory marker improvements by weeks 4 through 6. Those studies used intraperitoneal HNG, not subcutaneous native humanin at human-equivalent doses. Direct translation isn't supported. Community data is thin here; one documented self-experiment (1 mg twice daily for 15 days) noted subjective energy improvements, but no consistent pattern has emerged across protocols.
Weeks 6 to 10 (Cumulative Cellular Protection Phase): Mouse HNG studies at 4 mg/kg twice weekly (IP) showed reduced visceral fat, improved lean mass, and better metabolic markers by weeks 8 through 12. No SC native humanin animal data at human-equivalent doses exists to anchor expectations. Most community protocols run 8 to 12 weeks before attempting any assessment. High cost (around $1,368 for a 10-week moderate cycle) likely drives significant dropout before cycle completion.
Post-Cycle Weeks 11 to 15 (Off-Cycle Washout): No human washout data exists. Rodent PK suggests rapid clearance on the scale of minutes in mice, hours in rats. No rebound effects, tolerance, or receptor changes have been documented. Community reports indicate a return to pre-cycle subjective baseline with no discontinuation effects. No biomarker washout data is publicly available from any self-experiment.
Detailed Timeline: Science vs Community
No human onset timeline data. Rodent PK shows peak plasma at ~10 min (mice IP) or ~4 h (rats IP) with rapid clearance; brain tissue levels undetectable in rats after systemic injection. Human SC kinetics entirely unknown.
Some biohackers report mild subjective energy or cognitive clarity within the first 1–2 weeks. No objective data validates this; effect may be placebo or driven by co-administered peptides (MOTS-c, NAD+).
Animal models (HNG IP) show improvements in insulin sensitivity and inflammatory markers by weeks 4–6. Studies used IP injection of HNG at 2.5–4 mg/kg: not SC native humanin at human-equivalent doses. Direct translation is not supported.
Limited data. One documented anecdotal report (1 mg 2x/day × 15 days) noted subjective energy improvements. No consistent pattern across community protocols.
Mouse HNG studies (4 mg/kg 2x/week IP) showed reduced visceral fat and improved lean mass and metabolic markers by weeks 8–12. No SC native humanin animal data at human-equivalent doses exists to anchor expectations.
Most community protocols run 8–12 weeks before assessing results. No systematic outcome tracking found publicly. High cost likely drives significant dropout before cycle completion.
No human washout data. Rodent PK suggests rapid clearance (minutes in mice, hours in rats). No rebound pharmacology, tolerance, or receptor upregulation documented.
No community reports of discontinuation effects. Users report return to pre-cycle subjective baseline. No biomarker washout data available from any self-experiment.
Pharmacokinetics
Source: Chin et al. 2013 (PMID 23836030): ~30 min half-life in mice after IP injection of HNG, a humanin analog. In rats, HNG levels peaked at 4 hours and the half-life was much longer. Human PK data is unavailable.
Pharmacokinetics: Active Dose Over Time
t½ = ~30 min in mice (IP); >4 hours in rats (IP). Human half-life unknown.Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Humanin Legal?
Humanin is classified as a research-only peptide. It has no FDA approval, no IND application on record, and no completed human clinical trials. It is not a pharmaceutical drug and cannot be marketed for human consumption or therapeutic use.
Humanin (native or HNG analog) is sold online under "for research purposes only" labeling. No compounding pharmacy formulation exists. Humanin appears in none of FDA's 503A or 503B nomination categories (May 14, 2026; March 21, 2025).
Athletes should note that humanin's regulatory status under WADA has not been specifically addressed, but novel peptide hormones and their analogs generally fall under the S2 category (peptide hormones, growth factors, related substances) on the WADA Prohibited List. Competitive athletes should assume it is prohibited in and out of competition.
This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any research peptide.
Evidence grade: No human studies found (Peptide Evidence Gap, October 2026)
Who Should Consider Humanin
- Aging adults interested in mitochondrial-derived peptide research
- Researchers studying neurodegenerative disease and amyloid-beta pathways
- Individuals with metabolic dysfunction exploring preclinical compounds
- People interested in oxidative stress and mitochondrial support
Related Peptides
What Changed for Humanin
Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations
References
- [1]The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan (Aging 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents (Endocrinology 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Humanin decreases mitochondrial membrane permeability by inhibiting the membrane association and oligomerization of Bax and Bid proteins (JBC 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives (Biology 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Humanin and Alzheimer's disease: The beginning of a new field (BBA General Subjects 2022) (opens in a new tab)PubMed 34626746PubMed
- April 2026 (PMC3776863) (opens in a new tab)PubMed
- Reports 2020 (PMC10740898) (opens in a new tab)PubMed
- Reports 2020 (DOI: 10.1007/s12035-025-05198-5) (opens in a new tab)PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Humanin?
Emerging. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 20–40. Community mentions on Reddit: ~20–40 threads estimated (r/nootropics, r/longevity, r/Bioha. Open r/nootropics (opens in a new tab).
200 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.